Table 1 Patient characteristics.
IXA (n = 37) | IXA+BEV (n = 39) | |
|---|---|---|
Age in years, median (range) | 67 (50–88) | 67 (40–78) |
Race, % (N) | ||
White | 73% (27) | 80% (31) |
Black | 22% (8) | 10% (4) |
Other | 5% (2) | 10%(4) |
Ethnicity, % (N) | ||
Hispanic | 8% (3) | 3% (1) |
Non-Hispanic | 92% (34) | 95% (37) |
Unknown | 0 | 3% (1) |
Histology, % (N) | ||
Serous | 78% (29) | 87% (34) |
Carcinosarcoma | 6% (2) | 3% (1) |
Other | 16% (6) | 10% (4) |
ECOG Performance Status, % (N) | ||
0–1 | 84% (31) | 92% (36) |
2 | 16% (6) | 8 % (3) |
Prior Lines of Chemotherapy, % (N) | ||
≤3 | 49% (18) | 54% (21) |
>3 | 51% (19) | 46% (18) |
Prior PARP Inhibitor | ||
Yes | 38% (14) | 26% (10) |
No | 62% (23) | 74% (29) |
Prior Bevacizumab, % (N) | ||
Yes | 57% (21) | 54% (21) |
No | 43% (16) | 46% (18) |
Prior Weekly Paclitaxel (for first line treatment or treatment of recurrence), % (N) | ||
Yes | 35% (13) | 26% (10) |
No | 65% (24) | 74% (29) |
Prior Receipt of an AURELIA Regimen, % (N) | ||
- With Bevacizumab | ||
Weekly paclitaxel | 29% (2) | 33% (2) |
Pegylated liposomal doxorubicin | 29% (2) | 66% (4) |
Topotecan | 14% (1) | 0 |
> 1 AURELIA regimen | 29% (2) | 0 |
- Without Bevacizumab | ||
Weekly paclitaxel | 17% (2) | 11% (2) |
Pegylated liposomal doxorubicin | 58% (7) | 67% (12) |
Topotecan | 8% (1) | 17% (3) |
>1 AURELIA regimen | 17% (2) | 5% (1) |
Platinum Refractory/Resistant Disease, % (N) | ||
Refractory | 11% (4) | 26% (10) |
Resistant | 89% (33) | 74% (29) |
Taxane Refractory/Resistant Disease, % (N) | ||
Refractory | 27% (10) | 33% (13) |
Resistant | 24% (9) | 33% (13) |
Sensitive | 49% (18) | 33% (13) |
